6 completed, 4 active not recruiting, 2 terminated, 1 recruiting. 13 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 13 | Completed 6, Active not recruiting 4, Terminated 2, Recruiting 1 |
| Phase 1 | 2 | Active not recruiting 2 |
| Phase 3 | 2 | Active not recruiting 1, Completed 1 |
Follow Primary Peritoneal Serous Adenocarcinoma: new trials by email Literature Review of Primary Peritoneal Serous Adenocarcinoma trials Research Report on Primary Peritoneal Serous Adenocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion Bevacizumab, Biopsy, Biospecimen Collection - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Recruiting | Roswell Park Cancer Institute | 60 | 2023-04-27 | 2026-03-23 |
| Dual mTorc Inhibition in advanCed/Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer (of Clear Cell, Endometrioid and High Grade Serous Type, and Carcinosarcoma) Paclitaxel, TAK228 - Ovarian Cancer, Ovarian Neoplasms | Phase 2 | Completed | Imperial College London | 134 | 2018-09-21 | 2024-09-20 |
| Paclitaxel and Bevacizumab With or Without Emactuzumab in Treating Patients With Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Emactuzumab, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | M.D. Anderson Cancer Center | 9 | 2017-05-05 | 2024-03-13 |
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
| Testing the Combination of the Study Drugs Cediranib and Olaparib in Recurrent Ovarian Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 70 | 2016-05-23 | 2026-09-29 |
| Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer Cediranib, Cediranib Maleate, Computed Tomography - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 582 | 2016-05-03 | 2026-10-01 |
| MV-NIS or Investigator's Choice Chemotherapy in Treating Patients With Ovarian, Fallopian, or Peritoneal Cancer Bevacizumab, Gemcitabine Hydrochloride, Laboratory Biomarker Analysis - Fallopian Tube Carcinosarcoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Terminated | Mayo Clinic | 17 | 2015-03-13 | 2025-12-11 |
| MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer Laboratory Biomarker Analysis, Mesenchymal Stem Cell Transplantation, Oncolytic Measles Virus Encoding Thyroidal Sodium Iodide Symporter - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | Mayo Clinic | 34 | 2014-04-25 | 2026-08-24 |
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
| Elesclomol Sodium and Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Elesclomol Sodium, Paclitaxel - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | GOG Foundation | 58 | 2010-12-13 | 2021-10-20 |
| First-Line Treatment of Bevacizumab, Carboplatin, and Paclitaxel in Treating Participants With Stage III-IV Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Bevacizumab, Carboplatin, Paclitaxel - Fallopian Tube Carcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Phase 2 | Completed | M.D. Anderson Cancer Center | 33 | 2010-04-14 | 2022-10-28 |
| Cediranib Maleate and Olaparib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Peritoneal Cancer or Recurrent Triple-Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Cediranib Maleate - Fallopian Tube Carcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 / Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 155 | 2010-04-14 | 2026-07-14 |
| AZD2171 in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer cediranib maleate - Fallopian Tube Cancer, Primary Peritoneal Serous Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 47 | 2005-10-01 | 2015-11-09 |
Fallopian Tube Neoplasms (12) · Ovarian Neoplasms (10) · Brenner Tumor (4) · Carcinoma, Ovarian Epithelial (1) · Cystadenocarcinoma, Serous (1) · Triple Negative Breast Neoplasms (1)
Neoplasms (13) · Adnexal Diseases (12) · Fallopian Tube Diseases (12) · Female Urogenital Diseases (12) · Female Urogenital Diseases and Pregnancy Complications (12) · Genital Diseases (12) · Genital Diseases, Female (12) · Genital Neoplasms, Female (12) · Neoplasms by Site (12) · Urogenital Diseases (12) · Urogenital Neoplasms (12) · Endocrine Gland Neoplasms (11) · Endocrine System Diseases (11) · Gonadal Disorders (11) · Ovarian Diseases (11)
Paclitaxel (7) · Taxes (6) · Bevacizumab (5) · Disulfides (5) · Immunoglobulin G (5) · Magnetic Resonance Spectroscopy (4) · Specimen Handling (4) · cediranib (4) · Biopsy (3) · Doxorubicin (3) · Topotecan (3) · liposomal doxorubicin (3) · olaparib (3) · pembrolizumab (2) · Carboplatin (1)
National Cancer Institute (NCI) (5) · M.D. Anderson Cancer Center (2) · Mayo Clinic (2) · Roswell Park Cancer Institute (2) · GOG Foundation (1) · Imperial College London (1)
United States (12) · United Kingdom (2) · Canada (1) · Germany (1) · Japan (1) · Puerto Rico (1) · South Korea (1)
Emese Zsiros (2) · Joyce F Liu (2) · Anil K. Sood, MD (1) · Anil Sood (1) · Bradley J Monk (1) · David M Gershenson (1) · Evanthia Galanis, M.D. (1) · Evanthia Galanis, MD (1) · Jonathan Krell (1) · Jung-min Lee (1) · Ursula Matulonis (1)
PMID 23810467, PMID 25218906, PMID 30309721, PMID 33211063, PMID 34986897, PMID 35123694, PMID 35382842, PMID 37185961, PMID 39361946, PMID 39638782
U10CA180868 (3), U01CA062490 (2), UM1CA186709 (2), N01CM00071 (1), P30CA006516 (1), P50CA083639 (1), P50CA136393 (1), R01CA136547 (1), R01CA200507 (1), R01CA267690 (1), U10CA027469 (1), UM1CA186644 (1), UM1CA186686 (1), UM1CA186690 (1), UM1CA186691 (1)